Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

MCC19704 (Non Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this research to learn if we can improve the health of people diagnosed with stage III Lung Cancer.
What is the Condition Being Studied?
Lung Cancer (non small cell lung cancer)

Who Can Participate in the Study?

- Adults Diagnosed with Stage III Lung Cancer
- Have not received more than 1 cycle of chemotherapy
- Have not received immunotherapy for lung cancer before

Age Group
Adults

What is Involved?

If you choose to join this study you will:
- Complete normal radiation therapy every day for 6 weeks (M-F)
- Get the study drug (Ipilimumab) when you get radiation
- Get the other study drug (Nivolumab) once a month after radiation
- Continue treatment if it is helping up to 12 cycles

Study Details

Full Title
Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC. MCC 19704.
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101793
NCT: NCT03663166
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698